Treatment with dupilumab with concomitant topical corticosteroids led to rapid and sustained improvement in itch intensity and frequency in children 6-11 years of age with severe atopic dermatitis, revealed a post hoc analysis of a phase 3 trial LIBERTY AD PEDS (NCT03345914), presented at the Revolutionizing Atopic Dermatitis virtual symposium.

On the Peak Pruritus Numerical Rating Scale (NRS), treatment with dupilumab was found to be associated with a significant improvement from baseline in daily worst itch score through day 22 in the 300-mg q4w group and the 200-mg q2w group, compared with placebo (–29% vs. –30%, respectively; P less than or equal to .001 and P less than or equal to .05). Dupilumab treatment was also associated with a significant improvement from baseline in weekly average of daily worst itch score through week 16, compared with placebo (–55% vs. –58%; P less than or equal to .001). A higher daily proportion of dupilumab-treated patients attained a 2-point or more improvement in worst itch score, compared with placebo (51% vs. 49%; P less than or equal to .001 and P less than or equal to .05). The same association was noted for the daily proportion of dupilumab-treated patients attaining a 4-point or more improvement in worst itch score, compared with placebo (21% in both groups; P less than or equal to .05)… (Medscape)